GPCR Therapeutics USA

GPCR Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of therapeutics that target G protein-coupled receptor (GPCR) heteromers. The company's proprietary platform identifies specific GPCR pairs that interact to drive disease progression, allowing for the development of combination therapies with enhanced efficacy and reduced side effects. Their lead program, GPCR-101, is a CXCR4 antagonist being evaluated in combination with the beta-blocker propranolol for the treatment of multiple myeloma. By targeting the synergistic relationship between CXCR4 and beta-adrenergic receptors, GPCR Therapeutics aims to overcome drug resistance in hematologic malignancies and solid tumors.